期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

联合应用sIL-5Rα及sIL-13Rα2对支气管哮喘小鼠VCAM-1、STAT6水平的影响 被引量：2

Effects of sIL-5Rα and sIL-13Rα2 on VCAM-1 and STAT6 in bronchial asthma mouse
原文传递
导出
摘要 目的探讨联合应用可溶性白介素5受体α(sIL-5Rα)及可溶性白介素13受体α2(sIL-13Rα2)对支气管哮喘(简称哮喘)动物血管细胞黏附分子1(VCAM-1)、信号转导和转录激活因子6(STAT6)水平的影响。方法 50只BALB/c小鼠随机分为正常组、哮喘组、sIL-5Rα治疗组、sIL-13Rα2治疗组、联合sIL-5Rα及sIL-13Rα2治疗组(简称联合治疗组)。哮喘组和治疗组用鸡卵蛋白(OVA)和氢氧化铝致敏,用OVA激发,建立小鼠哮喘模型,正常组用生理盐水代替,其中sIL-5Rα治疗组、sIL-13Rα2治疗组及联合治疗组分别于诱发前30min给予腹腔注射100μgsIL-5Rα、sIL-13Rα2及联合应用sIL-5Rα及sIL-13Rα2各100μg,正常组和哮喘组激发前30min给予腹腔注射相同体积生理盐水。ELISA双抗体夹心法测定各组血清VCAM-1水平变化,免疫组织化学法和反转录-聚合酶链反应(RT-PCR)法检测各组小鼠肺组织STAT6水平变化。结果与正常组比较,哮喘组VCAM-1、STAT6含量明显升高(P<0.01);联合治疗组可有效降低VCAM-1、STAT6含量,与哮喘组比较差异有统计学意义(P<0.01);与单独治疗组相比,联合治疗组效果更明显(P<0.01)。结论联合应用sIL-5Rα及sIL-13Rα2可显著降低VCAM-1、STAT6含量,从而达到缓解和治疗哮喘的目的。 Objective To investigate the effects of soluble interleukin-5 receptor α （sIL-5Rα） and soluble interleukin-13 receptorα2 （sIL-13Rα2） on VCAM-1 and STAT6 in bronchial asthma （asthma） animal. Methods A total of 50 BALB/c mice were randomly divided into 5 groups：the normal group, the asthmatic group, the sIL-5Rα treatment group, the sIL-13Rα2 treatment group, the combination of sIL-5Rα and sIL-13Rα2 treatment group （the combined treatment group）. Mice in the latter 4 groups were sensitized with ovalbumin （OVA） and Al （OH）3,and challenged with OVA to establish asthmatic models, while mice in the normal group were treated with saline. Mice in the sIL-5Rα treatment group, the sIL-13Rα2 treatment group and the combined treatment group were injected intraperitoneally with sIL-5Rα （100 μg）,sIL-13Rα （100 μg） and the combination of sIL-5Rα （100 μg） and sIL-13Rα2 （100 μg） 30 min before challenged,while mice in normal group and asthmatic group received saline. Then the VCAM-1 level of serum were measured by ELISA, and level of STAT6 were measured by immunohistochemically and RT-PCR.Results Compared with the normal group, the level of VCAM-1 and STAT6 in the asthmatic group were higher （P0.01）.Compared with the asthmatic group, the combined treatment group can effectively reduced VCAM-1 and STAT6 level （P0.01）.Compared with single treatment, combined treatment group were more effective （P0.01）.Conclusions sIL-5Rα and sIL-13Rα2 inhibit IL-5 and IL-13 functions can reduce VCAM-1 and STAT6 levels, which achieve the purpose of mitigation and treatment of asthma.
作者 杨学敏 史海广 成家军 李志奎
机构地区 第四军医大学西京医院呼吸内科
出处 《中华哮喘杂志（电子版）》 CAS 2012年第1期15-18,共4页 Chinese Journal of Asthma(Electronic Version)
基金 国家自然科学基金资助项目(30770926)
关键词 可溶性白介素5受体α 可溶性白介素13受体α2 血管细胞黏附分子1 信号转导和转录激活因子6 哮喘 Soluble interleukin-5 receptor α Soluble interleukin-13 receptor α2 Vascular cell adhesion molecule-1 Singnal transducers and activators of transcription 6 Asthma
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Barthel SR,Jarjour NN,Mosher DF,et al.Dissection of the hyperadhesive phenotype of airway eosinophils in asthma.Am J Respir Cell Mol Biol,2006,35:378-386.
  • 2Darcan-Nicolaisen Y,Meinicke H.Fels G,et al.Small interferihg RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice.J Immunol,2009,182:7501-7508.
  • 3Trieu Y,Wen XY,Skinnider BF,et al.Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin'S lymphoma growth in vitro and in vivo.Cancer Res,2004,64:3271-3275.
  • 4Liu LY,Sedgwick JB,Bates ME,et al.Decreased expression of membrane IL-5 receptor alpha on human eosinophils:II.IL-5 down-modulates its receptor via a proteinase-mediated process,J Immunol,2002,169:6459-6466.
  • 5Chen W.Tabata Y,Gibson AM,et al.Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo.J Allergy Clin Immunol,2008,122:625-632.
  • 6Yasunaga S.Yuyama N,Arima K,et al.The negative-feedback regulation of the IL-13 signal by the IL-13 receptor alpha2 chain in bronchial epithelial cells.Cytokine-2003,24:293-303.
  • 7王袁园,周明辉,娄卫华.VCAM-1表达在上下呼吸道一致性的研究,临床耳鼻咽喉头颈外科杂志,2009,23:506-507,512.
  • 8Meyts I,Vanoirbeek JA-Hens G,et al.T-cell mediated late increase in bronchial tone after allergen provocation in a murine asthma model.C1in Immunol,2008.128:248-258.
  • 9Tomkinson A,Duez C,Cieslewicz G,et al.A murine IL-4 receptor antagonist that inhibits IL-4-and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness.J Immunol,2001,166:5792-5800.
  • 10Kim DY,Ryu SY,Lira JE,et al.Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model.Eur J Pharmac01,2007,557:76-86.

同被引文献23

  • 1Wegmann M. Targeting eosinophil biology in asthma therapy [J]. Am J Respir Cell Mol Biol, 2011, 45 (4): 667-674.
  • 2Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report [J]. Allergy, 2004, 59 (5): 469-478.
  • 3Busse WW, Ring J, Huss-Marp J, et a/. A review of treatment with mepolizumab, an anti-lL-5mAb, in hypereosinophilie synd- romes and asthma [J]. J Allergy Clin Immunol, 2010, 125(4): 803-813.
  • 4Lei JT, Mazumdar T, Martinez-Moezygemba M. Three lysine residues in the eommon β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquiti-nation, endocytosis, and signaling [J]. J Biol Chem, 2011, 286 (46): 40091-40103.
  • 5Scott CW, Logsdon N J, Wilkins DE, et O1. Molecular cloning of the guinea-pig IL-5 receptor alpha and beta subunits and reconstitution of a high affinity receptor [J]. Cytokine, 2000, 12 (7): 858-866.
  • 6Perez C, Vandesompele J, Vandenbroucke I, et al. Quantitative real time polymerase chain reaction for measurement of human interleukin-5 receptor alpha spliced isoforms mRNA [J]. BMC Biotechnol, 2003, 3( 1 ): 17-21.
  • 7Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease [J]. Cytokine, 2004, 28 (4-5): 152-157.
  • 8Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflamma- tion: from discovery to therapy [J]. Int Immunol, 2009, 21 ( 12): 1303-1309.
  • 9Busse WW, Katial R, Gossage D, et ol. Safety profile, phar- macokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma [J]. J Allergy Clin Immunol, 2010, 125 (6): 1237-1244.
  • 10Ailor E, Betenbaugh MJ. Modifying secretion and post-trans- lational processing in insect cells [J]. Curr Opin Biotechol, 1999, 10 (2): 142-145.

引证文献2

二级引证文献6

中华哮喘杂志（电子版）
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部